In PIONEER 6, WDAE were higher, with 27% of patients in the semaglutide 14 mg treatment group and 17% of patients in the placebo treatment group WDAE
Intended for use by healthcare professionals
Mild side effects may include pain at the injection site, nausea, or dizziness
Jensen, the team looked for incidence of chronic kidney disease (CKD) and acute kidney injury (AKI)
CT-388 and CT-868, developed by Carmot Therapeutics, are GIPR/GLP-1R agonists under investigation in obese patients, including those with type 1 diabetes (NCT04838405, NCT06062069)
The first phase III trial demonstrating that once-weekly subcutaneous semaglutide can maintain moderate weight loss with a favourable tolerability and safety profile